obesity-congress-diabetes-congress-2018-tracks

17 / 18

Page 44
Note:
O c t o b e r 1 5 - 1 6 , 2 0 1 8 | T o k y o , J a p a n
Obesity Congress 2018, Diabetes Congress 2018 & Vaccines Congress 2018 Biomedical Research | ISSN: 0976-1683| Volume 29
2nd WORLD OBESITY CONGRESS
2nd WORLD VACCINES AND IMMUNOLOGY CONGRESS
&
&
DIABETES AND ENDOCRINOLOGY
International Conference on
Joint Event on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
Pierre A Morgon, Biomed Res 2018, Volume 29 | DOI: 10.4066/biomedicalresearch-C5-013
SUCCESSFULLY ACTIVATING POSITIVE
BEHAVIORS OF THE STAKEHOLDERS
INVOLVED IN VACCINE PURCHASING
AND USAGE THROUGH TECHNOLOGICAL
ADVANCES
Pierre A Morgon
MRGN Advisors, Switzerland
The vaccine segment is anticipated to be one of the fastest growing one
of the healthcare industry and several leading firms have stepped up
vaccine investments in recent years. Unlike therapeutic agents, vaccines are
administered to healthy individuals only once or very infrequently during a
life time. Vaccines generate well-documented positive externalities, yet their
poor awareness and acceptability among vaccine end-users may contribute
to resurgence of transmissible diseases and consequently trigger govern-
mental interventions such as mandating vaccination. In addition to technical
and clinical development per the highest quality standards, bringing new vac-
cines to market requires carefully orchestrated programs targeting the mul-
tiple types of stakeholders along the entire value chain and addressing their
respective purchasing behavioral drivers. Against a backdrop of anti-vacci-
nation buzz and vaccine fatigue, successful global launch and sustainable
usage of a vaccine requires the development of a multi-pronged strategy
addressing all aspects in relation to acceptability (e.g. the motivation to im-
munize despite the quasi-disappearance of the disease), accessibility (e.g.
supply chain services), availability (e.g. mechanisms ensuring reliability of
supply) and affordability (e.g. tiered pricing policy taking country differences
in per capita income into account). Leveraging novel technological advances
can positively influence the ability to activate these levers successfully.
Pierre A Morgon is a Chief Executive Officer of MRGN
Advisors, a consultancy advising CEOs and investors
in the healthcare sector, and regional partner for Swit-
zerland at Mérieux Dévelopment, an evergreen invest-
ment fund. He is also holding the following board po-
sitions: Chairman of the Board of Virometix, Non-Ex-
ecutive Director to the Board of Theradiag, Non-Ex-
ecutive Director to the Board of Eurocine Vaccines,
Non-Executive Director to the Board of Vaccitech and
Non-Executive Director to the Board of Univercells. He
holds a Doctorate of Pharmacy, a master in Business
Law and a MBA.
BIOGRAPHY